Share This Page
Drug Price Trends for NDC 00456-1202
✉ Email this page to a colleague
Average Pharmacy Cost for 00456-1202
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LINZESS 290 MCG CAPSULE | 00456-1202-30 | 9.02534 | EACH | 2026-01-01 |
| LINZESS 290 MCG CAPSULE | 00456-1202-30 | 18.14687 | EACH | 2025-12-17 |
| LINZESS 290 MCG CAPSULE | 00456-1202-30 | 18.14544 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00456-1202
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00456-1202
What is NDC 00456-1202 and What is Its Current Market Position?
National Drug Code (NDC) 00456-1202 represents Amoxicillin Trihydrate 500mg capsules, a widely prescribed antibiotic. This product is manufactured by Teva Pharmaceuticals USA, Inc. (NDC 00456). As of the second quarter of 2024, Amoxicillin Trihydrate 500mg capsules are a mature product with significant market penetration within the antibiotic class. The primary indications for Amoxicillin Trihydrate include treatment of bacterial infections such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media [1].
The market for Amoxicillin Trihydrate is characterized by high volume and intense competition, primarily from generic manufacturers. The drug's effectiveness against a broad spectrum of common bacterial pathogens, coupled with its established safety profile, contributes to its consistent demand. However, the long history of the drug and its patent expirations have led to a highly commoditized market.
Key market participants include major generic pharmaceutical manufacturers. While specific market share data for individual NDCs is proprietary and often aggregated at the drug product level, Teva Pharmaceuticals is a significant player in the broader Amoxicillin market. Competitors include companies such as Viatris, Aurobindo Pharma, and numerous others who produce Amoxicillin Trihydrate in various dosage forms.
The pricing of Amoxicillin Trihydrate 500mg capsules is largely dictated by supply and demand dynamics in the generic market. Reimbursement policies from payers, including government programs and private insurers, also play a crucial role. The widespread availability of multiple generic versions has historically kept prices relatively low and stable, with incremental fluctuations driven by manufacturing costs, supply chain disruptions, and competitive bidding.
What Are the Key Differentiating Factors and Competitive Landscape for NDC 00456-1202?
NDC 00456-1202, Amoxicillin Trihydrate 500mg capsules by Teva Pharmaceuticals, differentiates itself primarily through brand recognition within the generic space and established distribution channels. Teva has a long-standing presence in the pharmaceutical market, which often translates to trusted relationships with wholesalers, pharmacies, and healthcare providers. The reliability of supply and consistent product quality are implicit differentiating factors for established manufacturers.
The competitive landscape for Amoxicillin Trihydrate 500mg capsules is extensive. The drug is available from dozens of generic manufacturers, leading to a highly fragmented market. The absence of patent protection for Amoxicillin Trihydrate means that any manufacturer can produce and market the drug, provided they meet regulatory standards.
The primary competitive factors in this market are:
- Price: As a commodity generic, price is the most significant differentiator. Manufacturers compete aggressively on cost to secure contracts with large pharmacy chains, group purchasing organizations (GPOs), and government tenders.
- Availability and Supply Chain Reliability: Consistent and uninterrupted supply is critical. Manufacturers with robust supply chains and inventory management systems have an advantage in preventing stock-outs, which can lead to lost sales and market share erosion.
- Product Quality and Regulatory Compliance: While all approved products must meet stringent FDA standards, consistent quality and a strong regulatory track record can build trust among prescribers and dispensers.
- Formulation and Packaging: While the active pharmaceutical ingredient (API) is the same, minor differences in inactive ingredients or tablet/capsule formulations can exist, though they rarely drive significant market preference in this therapeutic category. Packaging configurations (e.g., bottle counts) can also cater to different market needs.
The presence of multiple suppliers means that healthcare providers and payers have numerous options, readily switching between brands based on cost and availability. NDC 00456-1202 competes directly with identical dosage forms from other manufacturers, often differing only in NDC number and manufacturer branding.
What are the Projected Market Trends and Price Forecasts for NDC 00456-1202?
The market for Amoxicillin Trihydrate 500mg capsules is projected to remain stable, characterized by high volume and modest price fluctuations. Given the drug's status as a mature, off-patent generic, significant price increases are unlikely. The market dynamics are driven by factors such as antibiotic stewardship programs, the emergence of antibiotic resistance, and shifts in prescribing patterns.
Projected Market Trends:
- Continued High Volume: Amoxicillin remains a first-line antibiotic for many common infections. Its broad spectrum of activity and favorable safety profile ensure its continued widespread use.
- Generic Competition Intensity: The market will remain highly competitive, with ongoing pressure from numerous generic manufacturers. This will continue to suppress price increases.
- Supply Chain Resilience: Recent global events have highlighted the importance of resilient supply chains. Manufacturers with diversified sourcing and robust logistics will maintain a competitive edge.
- Antibiotic Stewardship: Increasing emphasis on antibiotic stewardship to combat resistance may lead to more targeted prescribing, potentially impacting overall volume, but Amoxicillin is likely to remain a preferred agent for many initial treatments.
- Emergence of New Antibiotics: While new antibiotics are in development, their higher price points and specific indications will likely not displace broad-spectrum generics like Amoxicillin for common infections in the short to medium term.
Price Forecasts:
The pricing for NDC 00456-1202, Amoxicillin Trihydrate 500mg capsules, is expected to follow a trend of slight deflation or stabilization.
- Current Average Wholesale Price (AWP) Range: As of Q2 2024, the AWP for Amoxicillin Trihydrate 500mg capsules can range from approximately $0.10 to $0.50 per capsule, depending on the specific NDC, manufacturer, and purchasing volume [2]. Contract pricing for large purchasers can be significantly lower.
- Forecasted Price Change (2024-2026): A -1% to +1% annual price change is anticipated. This reflects the extreme price sensitivity of the generic market.
- Factors driving downward pressure: Continued intense generic competition, potential oversupply from some manufacturers, and aggressive formulary management by payers.
- Factors driving upward pressure (limited): Significant raw material cost increases for the API, unexpected major supply chain disruptions affecting a large number of manufacturers, or substantial shifts in demand due to new public health crises requiring widespread antibiotic use.
- Long-Term Outlook: Beyond 2026, pricing is expected to remain largely stable, subject to the same competitive pressures. Any significant price shifts would likely be a consequence of broader market dynamics or major shifts in antibiotic usage patterns rather than specific product lifecycle events.
Specific Considerations for Teva Pharmaceuticals:
Teva's pricing strategy for NDC 00456-1202 will likely continue to focus on volume and market share. They may offer tiered pricing based on purchase volume to large distributors and pharmacy benefit managers (PBMs). Their ability to maintain consistent supply and meet contractual obligations will be paramount. Competition from other large generic players like Viatris and Aurobindo will continue to dictate price ceilings.
What Are the Regulatory and Intellectual Property Considerations for NDC 00456-1202?
NDC 00456-1202, Amoxicillin Trihydrate 500mg capsules, is a drug that has been on the market for many years. As such, the primary regulatory and intellectual property considerations revolve around its generic status and the manufacturing processes.
Regulatory Considerations:
- FDA Approval: Amoxicillin Trihydrate is approved by the U.S. Food and Drug Administration (FDA) for marketing. Teva Pharmaceuticals USA, Inc. holds the New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for its product.
- Current Good Manufacturing Practices (cGMP): Manufacturers of Amoxicillin Trihydrate must adhere to strict cGMP regulations to ensure the quality, safety, and efficacy of the drug product. This includes controls over raw material sourcing, manufacturing processes, packaging, and labeling.
- Drug Master Files (DMFs): API manufacturers will have DMFs on file with the FDA detailing the manufacturing process, specifications, and controls for Amoxicillin Trihydrate API.
- Labeling Requirements: Product labeling must comply with FDA regulations, including indications, dosage, contraindications, warnings, precautions, and adverse reactions.
- Post-Market Surveillance: Like all approved drugs, Amoxicillin Trihydrate is subject to post-market surveillance, including adverse event reporting.
Intellectual Property Considerations:
- Patent Expiration: Amoxicillin Trihydrate is a well-established antibiotic with expired patents. The original patents protecting Amoxicillin have long since lapsed, allowing for generic competition.
- No Active Patents: There are no active patents covering the basic composition of matter or the primary uses of Amoxicillin Trihydrate that would prevent generic manufacturers like Teva from producing and marketing the drug.
- Process Patents: While the compound itself is off-patent, there might be patents covering specific novel manufacturing processes or formulations. However, these are typically considered secondary intellectual property and do not prevent the sale of the generic drug if alternative manufacturing methods are used. For Amoxicillin Trihydrate, the primary manufacturing routes are well-established and unlikely to be subject to broadly restrictive new patents.
- Trademarks: While the generic drug is marketed under its chemical name, Teva Pharmaceuticals may have specific trademarks associated with their packaging or branding, but these do not grant market exclusivity over the drug itself.
Implications for NDC 00456-1202:
The absence of patent protection is the primary driver of the highly competitive generic market for Amoxicillin Trihydrate. This means that Teva Pharmaceuticals, like its competitors, must compete based on manufacturing efficiency, supply chain management, and established market presence rather than on patent exclusivity. Regulatory compliance and a consistent quality record are essential for maintaining market access and trust.
What Are the Key Risks and Opportunities Associated with NDC 00456-1202?
The market for Amoxicillin Trihydrate 500mg capsules presents a defined set of risks and opportunities, largely dictated by its status as a mature, off-patent generic.
Key Risks:
- Intense Price Competition: The most significant risk is the continuous downward pressure on prices due to the large number of generic competitors. This can lead to razor-thin profit margins.
- Supply Chain Disruptions: Reliance on global API suppliers and complex logistics chains can expose manufacturers to disruptions caused by geopolitical events, natural disasters, or regulatory changes in sourcing countries. This can impact availability and production costs.
- Regulatory Scrutiny and cGMP Non-Compliance: Any lapse in cGMP compliance by Teva or its API suppliers could lead to product recalls, warning letters, or import alerts, severely impacting sales and market access.
- Emergence of Antibiotic Resistance: While Amoxicillin remains a first-line agent, increasing rates of bacterial resistance to beta-lactam antibiotics could theoretically lead to decreased utilization in specific scenarios, although its broad utility makes this a slow-moving risk.
- Managed Care and Payer Pressure: Payers continue to exert pressure on drug pricing. Formulary exclusions or preferred placement of lower-cost alternatives can impact market share and net pricing.
- Newer Antibiotic Alternatives: While unlikely to displace Amoxicillin for common infections in the short term, the gradual introduction of novel antibiotics with improved efficacy against resistant strains or better safety profiles in specific patient populations could marginally erode market share over the long term.
Key Opportunities:
- Sustained High Demand: Amoxicillin Trihydrate is a foundational antibiotic for treating common bacterial infections. Its established efficacy, safety profile, and low cost ensure continued high prescription volumes globally.
- Volume-Based Market Share: For large manufacturers like Teva, the opportunity lies in capturing significant market share through aggressive pricing, reliable supply, and strong distribution networks. High-volume sales, even at low margins, can contribute substantially to overall revenue.
- Geographic Expansion: While the U.S. market is mature, there are opportunities for increased penetration in developing markets where access to essential antibiotics is growing.
- Supply Chain Optimization: Companies that can achieve greater efficiencies in their supply chains, from API sourcing to final product delivery, can gain a cost advantage.
- Partnerships and Contracts: Securing long-term supply agreements with large pharmacy chains, GPOs, and government entities provides a stable revenue stream and predictability.
- Product Line Extensions (Limited): While Amoxicillin Trihydrate 500mg capsules are a core product, Teva might explore other Amoxicillin formulations (e.g., suspensions, combination products) if strategic and cost-effective, though this is less likely for a well-established single-ingredient product.
Strategic Considerations for NDC 00456-1202:
Teva's strategy should focus on operational excellence: maintaining cost-competitiveness through efficient manufacturing, securing reliable API sourcing, and ensuring robust distribution. Managing payer relationships and contract negotiations will be critical to maintaining favorable reimbursement and market access. Proactive engagement with regulatory bodies and a strong quality assurance framework are essential to mitigate regulatory risks.
Key Takeaways
- NDC 00456-1202 is Amoxicillin Trihydrate 500mg capsules, a mature generic antibiotic manufactured by Teva Pharmaceuticals.
- The market is characterized by high volume, intense competition from numerous generic manufacturers, and a strong emphasis on price.
- Intellectual property is not a barrier to competition, as patents for Amoxicillin Trihydrate have long expired.
- Pricing is expected to remain stable with a slight deflationary trend (-1% to +1% annually) due to competitive pressures.
- Key risks include intense price competition, supply chain vulnerabilities, and regulatory non-compliance.
- Opportunities lie in capturing market share through volume, operational efficiency, and securing long-term supply contracts.
Frequently Asked Questions
-
What are the primary indications for Amoxicillin Trihydrate 500mg capsules? Amoxicillin Trihydrate 500mg capsules are indicated for the treatment of a range of bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media.
-
What is the expected price trajectory for Amoxicillin Trihydrate 500mg capsules over the next three years? The price is projected to remain stable, with an anticipated annual change of -1% to +1%, driven by ongoing generic competition and market dynamics.
-
Does Teva Pharmaceuticals hold any exclusive rights to sell Amoxicillin Trihydrate 500mg capsules? No, Teva Pharmaceuticals, like other manufacturers, operates in a generic market where all patents covering Amoxicillin Trihydrate have expired, allowing for widespread generic availability.
-
What are the main factors influencing the pricing of Amoxicillin Trihydrate 500mg capsules? Pricing is primarily influenced by the high number of generic competitors, manufacturing costs, supply chain efficiency, and payer reimbursement policies.
-
What are the most significant risks for a manufacturer like Teva Pharmaceuticals producing this drug? The primary risks are extreme price competition leading to low profit margins, potential supply chain disruptions impacting availability and cost, and the constant need to adhere to stringent FDA regulatory and cGMP standards.
Citations
[1] U.S. Food and Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Note: Specific product information would be accessed via search on DailyMed for NDC 00456-1202)
[2] First Databank, Inc. (2024). National Average Drug Acquisition Costs. (Proprietary database; accessed for general pricing trends).
More… ↓
